Tokyo, Oct. 11 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000059363) titled 'A Study to Identify Biomarkers That Can Predict the Effectiveness and Side Effects of Cancer Treatment in Patients with Thoracic Tumors' on Oct. 10.

Study Type: Observational

Primary Sponsor: Institute - Tottori University

Condition: Condition - Lung cancer, thymic carcinoma, thymoma, and malignant pleural mesothelioma Classification by malignancy - Malignancy Genomic information - NO

Objective: Narrative objectives1 - To explore blood and pleural effusion biomarkers predictive of adverse events associated with thoracic malignancy treatments, including cytotoxic chemotherapy, molecular targeted therapy, immune checkpoint inhibitors, antibody-drug conjugates, bispecific antibodies, bispecific T-cell engagers, and thoracic radiotherapy. Basic objectives2 - Others

Eligibility: Age-lower limit - 16 years-old <= Age-upper limit - Not applicable Gender - Male and Female Key inclusion criteria - Patients aged 16 years or older at the time of consent who are diagnosed with thoracic malignancies (lung cancer, thymic carcinoma, thymoma, or malignant pleural mesothelioma) and are scheduled to receive treatment with cytotoxic chemotherapy, molecular targeted agents, immune checkpoint inhibitors, antibody-drug conjugates, bispecific antibodies, bispecific T-cell engagers, or thoracic radiotherapy at the Division of Respiratory Medicine and Rheumatology, Tottori University Hospital. As control groups, patients aged 16 years or older at the time of consent who are diagnosed and treated at the Division of Respiratory Medicine and Rheumatology, Tottori University Hospital for non-malignant respiratory diseases, autoimmune diseases, allergic diseases, or infectious diseases, as well as those with thoracic malignancies not scheduled to undergo anticancer drug therapy or radiotherapy. In addition, healthy volunteers aged 18 years or older at the time of consent will be included. Key exclusion criteria - Patients who do not have samples required for the evaluation of this study, those who decline the use of their samples or information, and those whom the principal investigator judges to be inappropriate for participation in the study. Target Size - 400

Recruitment Status: Recruitment status - Enrolling by invitation Date of protocol fixation - 2025 Year 09 Month 12 Day Date of IRB - 2025 Year 10 Month 02 Day Anticipated trial start date - 2025 Year 10 Month 10 Day Last follow-up date - 2032 Year 03 Month 31 Day

To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000067874

Disclaimer: Curated by HT Syndication.